Month: May 2020

HOUSTON, May 15, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate developments.“We continued to make meaningful progress throughout the first quarter across all of our promising DNAbilize clinical development programs, even in the face of challenges associated with COVID-19.  During 2020, we expect to initiate safety testing of the triple combination of our lead candidate, prexigebersen, with decitabine and venetoclax as part of Stage 2 of our Phase 2 trial in patients with acute myeloid leukemia,” said Peter Nielsen, President...

Piraeus, Greece, May 14, 2020 (GLOBE NEWSWIRE) — GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) today announced the quarterly distributions on its preference units as follows:Contacts: Joseph Nelson Head of Investor Relations Phone: +1 212-223-0643 Email: ir@gaslogmlp.com About GasLog Partners GasLog Partners is a growth-oriented master limited partnership focused on owning, operating and acquiring LNG carriers under multi-year charters. GasLog Partners’ fleet consists of 15 LNG carriers with an average carrying capacity of approximately 158,000 cbm. GasLog Partners’ principal executive offices are located at 69 Akti Miaouli, 18537 Piraeus, Greece. Visit GasLog Partners’ website at http://www.gaslogmlp.com.

TULSA, Okla., May 15, 2020 (GLOBE NEWSWIRE) — AAON, Inc. (NASDAQ-AAON), today announced that its Board of Directors has declared a $0.03 increase in the Company’s regular semi-annual cash dividend, to $0.19 per share or $0.38 annually (an 18.75% increase from the previous $0.16 per share or $0.32 annually).  The next cash dividend will be payable on July 1, 2020, to stockholders of record as of the close of business on June 3, 2020.Gary D. Fields, President & CEO, stated, “We continually work to create meaningful value for our stockholders and are pleased our strong capital position allows us to do so through the increased cash dividend.”The company also today announced that its Board of Directors has approved a $1.25 million donation to the Winifred Montana Public School District, to be utilized in connection with the construction...

Piraeus, Greece, May 15, 2020 (GLOBE NEWSWIRE) — GasLog Ltd. (“GasLog” or “Company”) (NYSE: GLOG) today announced a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preference Shares, payable on July 1, 2020 for all shareholders of record as of June 30, 2020.Contacts: Joseph Nelson Head of Investor Relations Phone: +1 212-223-0643 Email: ir@gaslogltd.com About GasLog GasLog is an international owner, operator and manager of LNG carriers providing support to international energy companies as part of their LNG logistics chain. GasLog’s consolidated fleet consists of 35 LNG carriers. Of these vessels, 19 (14 on the water and five on order) are owned by GasLog, one has been sold to a subsidiary of Mitsui & Co., Ltd. and leased back to GasLog under a long-term bareboat charter and the remaining...

RESEARCH TRIANGLE PARK, N.C., May 15, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced companywide activities in support of hae day 🙂 2020, a global awareness day for hereditary angioedema (HAE).BioCryst stands in solidarity with the HAE community by participating in the annual HAE Global Walk. Since actual community walks cannot currently be organized, BioCryst employees around the world are joining virtually with others supporting hae day 🙂 by logging their steps and photographing their activities to raise awareness of HAE.“HAE is a rare genetic disorder that causes swelling to various parts of the body, and can be fatal when the swelling affects the throat due to the risk of suffocation,” said Henrik Balle Boysen, executive vice president and chief operating officer of HAE International, the...

All amounts in U.S. dollars unless otherwise statedTORONTO, May 15, 2020 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2020 and an update on matters following quarter end.Gerry Schwartz, Chairman and Chief Executive Officer of Onex, stated: “The most challenging times bring out the best in people.  Both within Onex and across businesses in our private equity portfolio, there were countless examples of employees ensuring where possible we could all work from home seamlessly; where not possible, ensuring employees were safe while serving their customers.  It was very gratifying to witness it all first-hand.”     HighlightsOnex reported a Q1 segment net loss of $1.1 billion ($10.34 per fully diluted share) comprised of a $985 million loss from the investing...

LAUSANNE, Switzerland, May 15, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase key programs focused on novel targets in neurodegenerative diseases at next week’s UBS Virtual Global Healthcare Conference (May 18–20, 2020).Speaking on May 20th, Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, will outline the cutting-edge science behind AC Immune’s therapeutic and diagnostic programs in TDP-43 and alpha-synuclein – which are amongst the most comprehensive in the field. Both targets are considered to be major pathologies in neurodegenerative diseases, and increasingly thought to be important co-pathologies in Alzheimer’s disease and Parkinson’s disease.  This highlights the...

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been selected for presentation at the upcoming 2020 American Association for Cancer Research (AACR) annual meeting, to be held virtuallyThe presentation details are as follows:Title: TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro, and cooperates with the glycoengineered anti-CD20 mAb, ublituximab, in in vivo mantle cell lymphoma modelsAbstract Number: 2939Available on Demand: Monday, June 22, 2020 at 9:00 AM ETSession Title: Combination Immunotherapies 2Presenting Author: Gaël Roué, PhD, Lymphoma Translational Group leader, Josep Carreras Leukaemia Research Institute (IJC)A copy...

-Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates-SEATTLE, May 15, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24, 2020. The presentations include preclinical data on lead candidate NL-201, as well as other applications of Neoleukin’s de novo protein design platform.Abstract #4518, a poster presentation, will feature preclinical data on NL-201, an IL-2 and IL-15 agonist designed to eliminate alpha binding for therapeutic use in cancer. Details of the structure and characteristics of the...

SOUTH SAN FRANCISCO, Calif., May 15, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it had received the CE mark approval for AlloSeq Tx 17, making it broadly available to transplant patients, laboratories and clinicians around the world.AlloSeq Tx 17 is the best in class solution for matching transplant donor organs to recipients, utilizing next generation Hybrid Capture technology for HLA testing. CareDx launched this novel technology during the American Society for Histocompatibility and Immunogenetics (ASHI) and BANFF Foundation for Allograft Pathology’s Joint meeting September 2019.“AlloSeq Tx 17...